SMARCA4‑deficient non‑small cell lung cancer with an <em>EGFR</em> mutation: A case report

Sun,Lijun; Fu,Qiong; Chen,Lijiang; Di,Meijuan; Cao,Jianhua

doi:10.3892/ol.2023.14100

SMARCA4‑deficient non‑small cell lung cancer with an EGFR mutation: A case report

Authors:
- Lijun Sun
- Qiong Fu
- Lijiang Chen
- Meijuan Di
- Jianhua Cao
View Affiliations

Affiliations: Department of Pathology, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang 311200, P.R. China, Department of Respiratory Medicine, Xiaoshan Affiliated Hospital of Wenzhou Medical University, Hangzhou, Zhejiang 311200, P.R. China
Published online on: October 13, 2023 https://doi.org/10.3892/ol.2023.14100
Article Number: 513
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SWI/SNF‑related, matrix‑associated, actin‑dependent regulator of chromatin, subfamily a, member 4 (SMARCA4)‑deficient non‑small cell lung cancer (dNSCLC) is a rare malignant tumor that originates in the lungs. It occurs more frequently in male smokers, and the epidermal growth factor receptor (EGFR) gene is often mutation‑free. In the present study, the case of a 60‑year‑old, non‑smoking female patient diagnosed with SMARCA4‑dNSCLC is reported. Biopsy of the tumor showed solid flaky, nest‑like infiltrating growth. Immunohistochemistry revealed the following: SMARCA4/BRG1(‑), SMARCB1/INI‑1(+), cytokeratin7 (+), cytokeratin 5.2 (+), CK5/6(+) and calretinin(+). The Ki‑67 positivity index was 75%, and the thyroid transcription factor‑1, NapsinA, p40, nuclear protein in testis, CD34, Sal‑like protein 4, SRY‑box transcription factor 2 and synaptophysin were negative. Molecular analysis showed mutations in both EGFR and TP53. The pathological diagnosis was SMARCA4‑dNSCLC with an EGFR gene mutation. The present case report could be used for broadening the pathological diagnosis of SMARCA4‑dNSCLC and for selecting appropriate treatment approaches.

View Figures

View References

1	Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A and Haller F: SMARCA4-deficient pulmonary adenocarcinoma: Clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1^neg/CK7^pos/HepPar-1^pos immunophenotype. Virchows Arch. 471:599–609. 2017. View Article : Google Scholar : PubMed/NCBI
2	Dagogo-Jack I, Schrock AB, Kem M, Jessop N, Lee J, Ali SM, Ross JS, Lennerz JK, Shaw AT and Mino-Kenudson M: Clinicopathologic characteristics of BRG1-deficient NSCLC. J Thorac Oncol. 15:766–776. 2020. View Article : Google Scholar : PubMed/NCBI
3	Naito T, Udagawa H, Umemura S, Sakai T, Zenke Y, Kirita K, Matsumoto S, Yoh K, Niho S, Tsuboi M, et al: Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden. Lung Cancer. 138:35–42. 2019. View Article : Google Scholar : PubMed/NCBI
4	Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, et al: SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 15:231–247. 2020. View Article : Google Scholar : PubMed/NCBI
5	Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul S, Arcila ME, et al: The Genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 26:5701–5708. 2020. View Article : Google Scholar : PubMed/NCBI
6	Sui YX, Jin L, Guo GD, Luo M, Qin XY, You LS and Chen LF: Clinicopathological analysis of the SMARCA4-deficient non-small cell lung carcinoma. Zhonghua Bing Li Xue Za Zhi. 50:1366–1368. 2021.(In Chinese). PubMed/NCBI
7	St Pierre R and Kadoch C: Mammalian SWI/SNF complexes in cancer: Emerging therapeutic opportunities. Curr Opin Genet Dev. 42:56–67. 2017. View Article : Google Scholar : PubMed/NCBI
8	Masliah-Planchon J, Bièche I, Guinebretière JM, Bourdeaut F and Delattre O: SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 10:145–171. 2015. View Article : Google Scholar : PubMed/NCBI
9	Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, et al: Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunol Res. 8:1075–1084. 2020. View Article : Google Scholar : PubMed/NCBI
10	Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, et al: SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 47:1200–1205. 2015. View Article : Google Scholar : PubMed/NCBI
11	Fernando TM, Piskol R, Bainer R, Sokol ES, Trabucco SE, Zhang Q, Trinh H, Maund S, Kschonsak M, Chaudhuri S, et al: Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. Nat Commun. 11:55512020. View Article : Google Scholar : PubMed/NCBI
12	La Fleur L, Falk-Sörqvist E, Smeds P, Berglund A, Sundström M, Mattsson JS, Brandén E, Koyi H, Isaksson J, Brunnström H, et al: Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. Lung Cancer. 130:50–58. 2019. View Article : Google Scholar : PubMed/NCBI
13	Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, Warth A and Agaimy A: SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: Immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol. 26:47–51. 2017. View Article : Google Scholar : PubMed/NCBI
14	Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S and Jain D: SMARCA4/BRG1-deficient non-small cell lung carcinomas: A case series and review of the literature. Arch Pathol Lab Med. 145:90–98. 2021. View Article : Google Scholar : PubMed/NCBI
15	Jin YP, Wang L, Wang Y, Wu DY, Zhang H and Xia QX: [Gastric SWI/SNF complex deletion-associated undifferentiated carcinoma with rhabdoid phenotype: A clinicopathological and molecular analysis]. Zhonghua Bing Li Xue Za Zhi. 51:1229–1234. 2022.(In Chinese). PubMed/NCBI
16	Liu SY, Mok T and Wu YL: Novel targeted agents for the treatment of lung cancer in China. Cancer. 121 (Suppl 17):S3089–S3096. 2015. View Article : Google Scholar
17	Tsao MS, Nicholson AG, Maleszewski JJ, Marx A and Travis WD: Introduction to 2021 WHO classification of thoracic tumors. J Thorac Oncol. 17:e1–e4. 2022. View Article : Google Scholar : PubMed/NCBI
18	Bell EH, Chakraborty AR, Mo X, Liu Z, Shilo K, Kirste S, Stegmaier P, McNulty M, Karachaliou N, Rosell R, et al: SMARCA4/BRG1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer. Clin Cancer Res. 22:2396–2404. 2016. View Article : Google Scholar : PubMed/NCBI